Navigation Links
Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillion's Ovarian Cancer Test
Date:11/28/2012

m Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty of finding a suitable successor chief executive officer; (7) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (8) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission (SEC). All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conju
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Saddleback Memorial Named First Robotic Training Epicenter for Gynecologic Surgery in Orange County
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
5. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
6. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
7. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
8. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
9. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
11. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011  Thoratec (NASDAQ: THOR), a world leader in device-based ... failing hearts, said today it will be participating in ... Tuesday, December 13. Taylor C. Harris, Senior ... an update on the company, beginning at 10:15 a.m., ...
...  VolitionRX Limited (VNRX.OB), a life sciences company focused on ... it will issue US$1,110,000 worth of shares of its ... issuance is the final requirement of the Share Purchase ... June 2011) between ValiRx and Singapore Volition Pte Limited, ...
Cached Medicine Technology:VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement 2
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... WA April 18, 2014) Benaroya Research Institute ... research how blocking a particular molecule in metastatic breast ... the number of lung metastases. BRI scientists have found ... can shrink tumors by 60 - 80 percent and ... the lung. The $1.8 million five-year grant comes from ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... Oct. 15 One Heartland will host "S,more to Love", a ... Open House Lofts, NYC to benefit Birch Family Camp. , Celebrating ... (over 200 family members) from the 5 boroughs of NYC, along ... building at a camp facility located in the Hudson Valley. ...
... 15 The Longaberger Company is teaming up with the ... against breast cancer. As part of the "Crucial Catch" campaign ... players - in partnership with the American Cancer Society - ... feature players, coaches and referees wearing pink game apparel to ...
... TALLAHASSEE, Fla. -- A Florida State University College of Medicine ... Institutes of Health (NIH) totaling $2.4 million to continue her ... months. Amy Wetherby is director of the Autism Institute ... WORDS Project has screened children to identify early red flags ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... Oct. 15 Astrup Drug Inc. has announced ... (ECRS) point-of-sale retail automation suite in their 11 ... selected by Astrup Drug to seamlessly automate their ... convenience/fuel integration, warehousing, front-end inventory control, and centralized ...
... for Presentation Also Nominated for Prestigious Prize , ... nine abstracts based on research by a total of 15 ... doctors, researchers and psychological social workers will be featured this ... meeting in Atlanta. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090203/DC66439LOGO ...
Cached Medicine News:Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 3Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Astrup Drug Implements ECRS Retail Solution Suite to Address Diverse Business Requirements 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 3Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 4
Softsplint after bunion surgery. Hook-and-loop closure. Maintains hallux positioning and metatarsophalangeal alignment. Washable....
... The Pediatric Ankle Cryo/Cuff is specifically designed ... 7). Using a combination of controlled compression ... and pain. The Pediatric Ankle Cryo/Cuff is ... hemorrhagic episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff ...
... Air-Stirrup Plus combines the clinically proven ... wrap. In addition, a comprehensive instruction ... Plus and provides information on treatment ... ankle sprain management.,Each Air-Stirrup Ankle Brace ...
... Full Transportability: Innovative design allows ... plug in for therapy or when ... Controller: Choose the prophylactic method to ... or both simultaneously. ,Automatic Garment Detection: ...
Medicine Products: